ACA
BSTC

Abdiel Capital Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Abdiel Capital Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-337,759
Closed -$11.8M – 8
2016
Q1 		$11.8M Sell
337,759
-121,918
-27% -$4.47M 5.16% 7
2015
Q4 		$19.8M Buy
+459,677
New +$23M 9.6% 4

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Abdiel Capital Advisors's BSTC Position: Q2 2016 in Review

Abdiel Capital Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2016, closing a stake of 337,759 shares — an estimated $11.8M sold.

Abdiel Capital Advisors first reported a position in BSTC in Q4 2015 and held it in 2 quarters. The position peaked at $19.8M in Q4 2015. 90 funds tracked by Wall St. Rank hold BSTC as of Q2 2016.

  • Abdiel Capital Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q2 2016 after selling out during the quarter.
  • Abdiel Capital Advisors sold 337,759 BioSpecifics Technologies Corp. shares in Q2 2016, an estimated $11.8M.
  • Abdiel Capital Advisors first reported a position in BioSpecifics Technologies Corp. in Q4 2015 and held it in 2 quarters.
  • Abdiel Capital Advisors's BioSpecifics Technologies Corp. position peaked at $19.8M in Q4 2015.
  • 90 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2016.

Based on Abdiel Capital Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.